PMVP PMV Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1699382 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-7.0%
TTM EPS YoY1.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-99.4%
ROA-72.2%
ROIC (approx.)-100.2%
Asset turnover—
Leverage & solvency
Liabilities / assets48.7%
Debt / equity0.00x
Current ratio9.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $16.06M | $14.68M | $15.33M | $15.83M | $18.21M | $18.40M | $17.44M | $13.77M |
| SG&A expense | $4.00M | $4.21M | $3.69M | $3.42M | $4.31M | $4.48M | $4.12M | $11.40M |
| Operating income | -$20.06M | -$18.88M | -$19.02M | -$19.24M | -$22.52M | -$22.88M | -$21.56M | -$25.17M |
| Pretax income | -$34.38M | -$18.08M | -$18.04M | -$18.01M | -$21.07M | -$21.20M | -$19.63M | -$23.00M |
| Income tax | -$7,000 | $3,000 | — | $26,000 | -$6,000 | $5,000 | -$2.20M | $0 |
| Net income | -$34.37M | -$18.09M | -$18.04M | -$18.04M | -$21.06M | -$21.21M | -$17.44M | -$23.00M |
| EBITDA | -$20.04M | -$18.86M | -$18.98M | -$19.21M | -$22.49M | -$22.85M | -$21.53M | -$25.13M |
| EPS (basic) | -0.52 | -0.34 | -0.34 | — | -0.40 | -0.41 | -0.34 | — |
| EPS (diluted) | -0.52 | -0.34 | -0.34 | — | -0.40 | -0.41 | -0.34 | — |
| Weighted avg. shares (diluted) | 66.23M | 53.39M | 53.33M | — | 52.99M | 52.01M | 51.95M | — |
| Banking | ||||||||
| Net interest income | $830,000 | $788,000 | $980,000 | $1.23M | $1.48M | $1.69M | $1.94M | $2.29M |
| Balance sheet | ||||||||
| Cash & equivalents | $19.99M | $12.47M | $39.13M | $37.98M | $36.34M | $44.13M | $51.34M | $40.88M |
| Short-term investments | $82.57M | $66.96M | $54.42M | $74.96M | $92.91M | $98.15M | $109.05M | $128.58M |
| Current assets | $104.89M | $81.41M | $95.78M | $115.23M | $132.45M | $145.31M | $163.50M | $175.66M |
| PP&E, net | $131,000 | $154,000 | $203,000 | $237,000 | $255,000 | $287,000 | $376,000 | $409,000 |
| Total assets | $111.40M | $82.07M | $96.56M | $116.56M | $133.84M | $152.85M | $170.61M | $191.29M |
| Current liabilities | $10.69M | $10.57M | $8.60M | $11.41M | $12.30M | $11.61M | $9.76M | $14.37M |
| Total liabilities | $54.30M | $10.57M | $8.60M | $11.85M | $12.85M | $12.25M | $10.50M | $15.21M |
| Shareholders' equity | $57.11M | $71.50M | $87.97M | $104.71M | $121.00M | $140.60M | $160.11M | $176.08M |
| Shares outstanding | 75.53M | 53.46M | 53.33M | 53.33M | 52.99M | 52.99M | 51.95M | 51.94M |
| Cash flow statement | ||||||||
| Operating cash flow | -$18.18M | -$14.58M | -$19.68M | -$17.19M | -$19.82M | -$18.30M | -$18.27M | -$16.66M |
| Capital expenditure | $0 | $0 | $0 | $15,000 | -$1,000 | $11,000 | $4,000 | $56,000 |
| Free cash flow | -$18.18M | -$14.58M | -$19.68M | -$17.20M | -$19.82M | -$18.31M | -$18.27M | -$16.72M |
| Investing cash flow | -$21.20M | -$12.23M | $20.82M | $18.44M | $12.03M | $10.99M | $28.71M | $7.74M |
| Financing cash flow | $46.91M | $143,000 | $0 | $392,000 | $0 | $103,000 | $10,000 | $172,000 |
| Depreciation & amortization | $23,000 | $24,000 | $34,000 | $33,000 | $32,000 | $32,000 | $37,000 | $39,000 |
| Stock-based compensation | $1.60M | $1.54M | $1.39M | $1.36M | $1.38M | $1.67M | $1.51M | $1.27M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.